Lantheus (LNTH) revenue breakdown

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $6.3B

By segment, U.S. is the largest at 87% of fiscal 2020 revenue, growing 3% a year over 4 years.

By product, PYLARIFY is the largest at 66% of fiscal 2023 revenue; DEFINITY grew fastest, 16% a year over 5 years.

Revenue by segment

Fiscal years, as Lantheus reports them in its 10-K filings; fiscal 2020 total $339M.

Segments20162017201820192020Share
U.S.$257M$290M$289M$304M$295M 87%
International$44M$41M$55M$43M$45M 13%

Revenue by product

Fiscal years, as Lantheus reports them in its 10-K filings; fiscal 2023 total $1.3B.

Products201620172018201920202023Share
PYLARIFY—————$851M 66%
DEFINITY$132M$157M$183M$218M$213M$280M 22%
TechneLite$99M$105M$99M$87M$86M$87M 7%
Strategic partnerships and other revenue—————$52M 4%
Other precision diagnostics—————$23M 2%
Other radiopharmaceutical oncology—————$3M 0%
Other$71M$69M———— —
Other nuclear——$74M$60M$59M— —
Rebates and allowances——-$13M-$17M-$19M— —

Revenue by region

Fiscal years, as Lantheus reports them in its 10-K filings; fiscal 2025 total $1.5B.

Regions201620172018202320242025Share
United States$257M$290M$289M$1.3B$1.5B$1.5B 95%
Rest of world———$34M$49M$83M 5%
All other$44M$41M$55M——— —
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LNTH.
Open LNTH in Investingly

Questions

Where does Lantheus make its money?

In fiscal 2020, by segment: U.S. $295M, International $45M.

From Lantheus's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.